Human Influenza Vaccine Composition
An advisory group of experts, convened by the WHO Global Influenza Programme, analyze biannually influenza virus surveillance data generated by the Global Influenza Surveillance and Response System (GISRS) and issues formal recommendation for the composition of influenza vaccines for either northern or southern hemisphere influenza seasons.
High yield candidate vaccine viruses are developed by collaboration of laboratories involved in developing reassortants and WHO Collaborating Centres (CCs).
Once developed, these candidate reassortants are sent to WHO CCs for characterization of their antigenic and genetic properties before being released to interested institutions on request. Reference reagents are subsequently developed and standardized by Essential Regulatory Laboratories (ERLs), in collaboration with vaccine manufacturers.
2025 Southern Hemisphere Influenza Season
27 September 2024
Recommended composition of influenza virus vaccines for use in the 2025 Southern Hemisphere influenza season.
It is recommended that trivalent influenza vaccines for use in the 2025 southern hemisphere influenza season contain the following:
Egg-based vaccines
an A/Victoria/4897/2022 (H1N1)pdm09-like virus (EPI_ISL_16714268);
an A/Croatia/10136RV/2023 (H3N2)-like virus (EPI_ISL_19296516); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459).
Cell culture- or recombinant-based Vaccines
an A/Wisconsin/67/2022 (H1N1)pdm09-like virus (EPI_ISL_15928563);
an A/District Of Columbia/27/2023 (H3N2)-like virus (EPI_ISL_18937823); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345).
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2025 Southern Hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:
(egg) a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_168822)
(cell) a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_161843).
Source: World Health Organization
2024-2025 Northern Hemisphere Influenza Season
23 February 2024
The WHO recommends that trivalent vaccines for use in the 2024-2025 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/4897/2022 (H1N1)pdm09-like virus; (EPI_ISL_16714268)
an A/Thailand/8/2022 (H3N2)-like virus; (EPI_ISL_16014504)
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; (EPI_ISL_1519459)
Cell- or recombinant-based Vaccines
an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; (EPI_ISL_15928563)
an A/Massachusetts/18/2022 (H3N2)-like virus; (EPI_ISL_13897304) and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. (EPI_ISL_983345)
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2024-2025 northern hemisphere influenza season: While the B/Yamagata lineage vaccine component should be excluded as it is no longer warranted, where quadrivalent vaccines are still in use, the B/Yamagata lineage component remains unchanged:
Egg-based Vaccines
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_168822)
Cell- or recombinant-based Vaccines
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_161843)
Source: World Health Organization
2024 Southern Hemisphere Influenza Season
29 September 2023
Recommended composition of influenza virus vaccines for use in the 2024 Southern Hemisphere influenza season.
It is recommended that trivalent influenza vaccines for use in the 2024 southern hemisphere influenza season contain the following:
Egg-based vaccines
an A/Victoria/4897/2022 (H1N1)pdm09-like virus (EPI_ISL_16714268);
an A/Thailand/8/2022 (H3N2)-like virus (EPI_ISL_16014504); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459).
Cell culture- or recombinant-based Vaccines
an A/Wisconsin/67/2022 (H1N1)pdm09-like virus (EPI_ISL_15928563);
an A/Massachusetts/18/2022 (H3N2)-like virus (EPI_ISL_16968012); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345).
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 Southern Hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:
(egg) a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_168822)
(cell) a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_161843).
Source: World Health Organization
2023-2024 Northern Hemisphere Influenza Season
24 February 2023
The WHO recommends that trivalent vaccines for use in the 2023-2024 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/4897/2022 (H1N1)pdm09-like virus; (EPI_ISL_16714268)
an A/Darwin/9/2021 (H3N2)-like virus; (EPI_ISL_2233240)
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; (EPI_ISL_1519459)
Cell- or recombinant-based Vaccines
an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; (EPI_ISL_15928563)
an A/Darwin/6/2021 (H3N2)-like virus; (EPI_ISL_3534319) and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. (EPI_ISL_983345)
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2023-2024 northern hemisphere influenza season, the WHO recommends inclusion of the following as the B/Yamagata lineage component:
Egg-based Vaccines
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_168822)
Cell- or recombinant-based Vaccines
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_161843)
Source: World Health Organization
2023 Southern Hemisphere Influenza Season
23 September 2022
Recommended composition of influenza virus vaccines for use in the 2023 Southern Hemisphere influenza season.
It is recommended that quadrivalent vaccines for use in the 2023 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Sydney/5/2021 (H1N1)pdm09-like virus (EPI_ISL_7458682);
an A/Darwin/9/2021 (H3N2)-like virus (EPI_ISL_2233240);
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459); and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_168822).
Cell- or recombinant-based Vaccines
an A/Sydney/5/2021 (H1N1)pdm09-like virus (EPI_ISL_8767089;
an A/Darwin/6/2021 (H3N2)-like virus (EPI_ISL_3534319);
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345); and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_161843).
It is recommended that trivalent influenza vaccines for use in the 2023 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Sydney/5/2021 (H1N1)pdm09-like virus (EPI_ISL_7458682);
an A/Darwin/9/2021 (H3N2)-like virus (EPI_ISL_2233240); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459).
Cell- or recombinant-based Vaccines
an A/Sydney/5/2021 (H1N1)pdm09-like virus (EPI_ISL_8767089;
an A/Darwin/6/2021 (H3N2)-like virus (EPI_ISL_3534319); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345).
Source: World Health Organization
2022-2023 Northern Hemisphere Influenza Season
25 February 2022
Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season.
It is recommended that quadrivalent influenza vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus; (EPI_ISL_417210)
an A/Darwin/9/2021 (H3N2)-like virus; (EPI_ISL_2233240)
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; (EPI_ISL_1519459) and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_168822)
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; (EPI_ISL_404460)
an A/Darwin/6/2021 (H3N2)-like virus; (EPI_ISL_2233238)
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; (EPI_ISL_983345) and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_161843)
It is recommended that trivalent influenza vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus; (EPI_ISL_417210)
an A/Darwin/9/2021 (H3N2)-like virus; (EPI_ISL_2233240)
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; (EPI_ISL_1519459)
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; (EPI_ISL_404460)
an A/Darwin/6/2021 (H3N2)-like virus; (EPI_ISL_2233238) and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. (EPI_ISL_983345)
Source: World Health Organization
2022 Southern Hemisphere Influenza Season
24 September 2021
Recommended composition of influenza virus vaccines for use in the 2022 Southern Hemisphere influenza season.
It is recommended that quadrivalent vaccines for use in the 2022 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus (EPI_ISL_417210);
an A/Darwin/9/2021 (H3N2)-like virus (EPI_ISL_2233240);
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459); and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_168822).
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus (EPI_ISL_404460);
an A/Darwin/6/2021 (H3N2)-like virus (EPI_ISL_3534319);
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345); and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (EPI_ISL_161843).
It is recommended that trivalent influenza vaccines for use in the 2022 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus (EPI_ISL_417210);
an A/Darwin/9/2021 (H3N2)-like virus (EPI_ISL_2233240); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_1519459).
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus (EPI_ISL_404460);
an A/Darwin/6/2021 (H3N2)-like virus (EPI_ISL_3534319); and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (EPI_ISL_983345).
Source: World Health Organization
2021-2022 Northern Hemisphere Influenza Season
26 February 2021
Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season.
It is recommended that quadrivalent influenza vaccines for use in the 2021 - 2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus; (EPI_ISL_417210)
an A/Cambodia/e0826360/2020 (H3N2)-like virus; (EPI_ISL_806547)
a B/Washington/02/2019 (B/Victoria lineage)-like virus; (EPI_ISL_352076) and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_168822)
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; (EPI_ISL_404460)
an A/Cambodia/e0826360/2020 (H3N2)-like virus; (EPI_ISL_944639)
a B/Washington/02/2019 (B/Victoria lineage)-like virus; (EPI_ISL_347829) and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. (EPI_ISL_161843)
It is recommended that trivalent influenza vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus; (EPI_ISL_417210)
an A/Cambodia/e0826360/2020 (H3N2)-like virus; (EPI_ISL_806547) and
a B/Washington/02/2019 (B/Victoria lineage)-like virus. (EPI_ISL_352076)
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; (EPI_ISL_404460)
an A/Cambodia/e0826360/2020 (H3N2)-like virus; (EPI_ISL_944639) and
a B/Washington/02/2019 (B/Victoria lineage)-like virus. (EPI_ISL_347829)
Source: World Health Organization
2021 Southern Hemisphere Influenza Season
25 September 2020
Recommended composition of influenza virus vaccines for use in the 2021 Southern Hemisphere influenza season.
It is recommended that quadrivalent vaccines for use in the 2021 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2021 southern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Source: World Health Organization
2020-2021 Northern Hemisphere Influenza Season
28 February 2020
Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season.
It is recommended that quadrivalent influenza vaccines for use in the 2020 - 2021 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2020-2021 northern hemisphere influenza season contain the following:
Egg-based Vaccines
an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines
an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Source: World Health Organization
2020 Southern Hemisphere Influenza Season
27 September 2019
Recommended composition of influenza virus vaccines for use in the 2020 Southern Hemisphere influenza season. It is recommended that quadrivalent vaccines for use in the 2020 southern hemisphere influenza season contain the following:
an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
an A/South Australia/34/2019 (H3N2)-like virus;
a B/Washington/02/2019-like (B/Victoria lineage) virus;
and a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.
It is recommended that trivalent influenza vaccines for use in the 2020 southern hemisphere influenza season contain the following:
an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
an A/South Australia/34/2019 (H3N2)-like virus;
and a B/Washington/02/2019-like (B/Victoria lineage) virus.
Source: World Health Organization
2019-2020 Northern Hemisphere Influenza Season
21 February 2019 (updated on 21 March 2019)
Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. It is recommended that egg based quadrivalent vaccines for use in the 2019-2020 northern hemisphere influenza season contain the following:
an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
an A/Kansas/14/2017 (H3N2)-like virus;*
a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019-2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.
* The A(H3N2) component was recommended on 21 March 2019.
Source: World Health Organization
2019 Southern Hemisphere Influenza Season
27 September 2018
Recommended composition of influenza virus vaccines for use in the 2019 Southern Hemisphere influenza season. It is recommended that egg based quadrivalent vaccines for use in the 2019 Southern Hemisphere influenza season contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Switzerland/8060/2017 (H3N2)-like virus;
a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that egg based trivalent vaccines for use in the 2019 Southern Hemisphere influenza season contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Switzerland/8060/2017 (H3N2)-like virus; and
a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage).
It is recommended that the A(H3N2) component of non-egg based vaccines for use in the 2019 Southern Hemisphere influenza season be an A/Singapore/INFIMH-16-0019/2016-like virus together with the other vaccine components as indicated above.
Source: World Health Organization
2018-2019 Northern Hemisphere Influenza Season
22 February 2018
Recommended composition of influenza virus vaccines for use in the 2018-2019 Northern Hemisphere influenza season. It is recommended that quadrivalent vaccines for use in the 2018-2019 northern hemisphere influenza season contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.
Source: World Health Organization
2018 Southern Hemisphere Influenza Season
28 September 2017
Recommended composition of influenza virus vaccines for use in the 2018 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2018 influenza season (Southern Hemisphere winter) contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
a B/Phuket/3073/2013-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2017-2018 Northern Hemisphere Influenza Season
2 March 2017
Recommended composition of influenza virus vaccines for use in the 2017-2018 Northern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere influenza season contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.
Source: World Health Organization
2017 Southern Hemisphere Influenza Season
29 September 2016
Recommended composition of influenza virus vaccines for use in the 2017 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2017 influenza season (Southern Hemisphere winter) contain the following:
an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.
Source: World Health Organization
2016-2017 Northern Hemisphere Influenza Season
25 February 2016
Recommended composition of influenza virus vaccines for use in the 2016-2017 Northern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2016-2017 influenza season (Northern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus; e.g. EPI_ISL/30485
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.
Source: World Health Organization
2016 Southern Hemisphere Influenza Season
24 September 2015
Recommended composition of influenza virus vaccines for use in the 2016 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2016 influenza season (Southern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.
Source: World Health Organization
2015-2016 Northern Hemisphere Influenza Season
26 February 2015
Recommended composition of influenza virus vaccines for use in the 2015-2016 Northern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2015-2016 influenza season (Northern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Switzerland/9715293/2013 (H3N2)-like virus;
a B/Phuket/3073/2013-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2015 Southern Hemisphere Influenza Season
25 September 2014
Recommended composition of influenza virus vaccines for use in the 2015 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2015 influenza season (Southern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Switzerland/9715293/2013 (H3N2)-like virusa;
a B/Phuket/3073/2013-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
aA/South Australia/55/2014, A/Norway/466/2014 and A/Stockholm/6/2014 are A/Switzerland/9715293/2013-like viruses
Source: World Health Organization
2014-2015 Northern Hemisphere Influenza Season
20 February 2014
Recommended composition of influenza virus vaccines for use in the 2014-2015 Northern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2014-2015 influenza season (Northern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Texas/50/2012 (H3N2)-like virus;
a B/Massachusetts/2/2012-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2014 Southern Hemisphere Influenza Season
26 September 2013
Recommended composition of influenza virus vaccines for use in the 2014 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2014 influenza season (Southern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virusa;
an A/Texas/50/2012 (H3N2)-like virusb*;
a B/Massachusetts/2/2012-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
aA/Christchurch/16/2010 is an A/California/7/2009-like virus.
bA/Texas/50/2012 is an A(H3N2) virus that following adaptation to growth in eggs has maintained antigenic properties similar to the majority of recently circulating cell-propagated A(H3N2) viruses including A/Victoria/361/2011.
Source: World Health Organization
2013-14 Northern Hemisphere Influenza Season
21 February 2013
Recommended composition of influenza virus vaccines for use in the 2013-14 Northern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2013-14 influenza season (northern hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virusa;
an A(H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011b*;
a B/Massachusetts/2/2012-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virusc.
aA/Christchurch/16/2010 is an A/California/7/2009-like virus;
bA/Texas/50/2012 is an A(H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;
cB/Brisbane/33/2008 is a B/Brisbane/60/2008-like virus.
* It is recommended that A/Texas/50/2012 is used as the A(H3N2) vaccine component because of antigenic changes in earlier A/Victoria/361/2011-like vaccine viruses (such as IVR-165) resulting from adaptation to propagation in eggs.
Source: World Health Organization
2013 Southern Hemisphere Influenza Season
20 September 2012
Recommended composition of influenza virus vaccines for use in the 2013 Southern Hemisphere influenza season. It is recommended that trivalent vaccines for use in the 2013 influenza season (Southern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus *;
an A/Victoria/361/2011 (H3N2)-like virus **;
a B/Wisconsin/1/2010-like virus ***;
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus ****.
* A/Christchurch/16/2010 is an A/California/7/2009-like virus;
** A/Ohio/2/2012, A/Maryland/2/2012, A/South Australia/30/2012, A/Brisbane/1/2012 and A/Brisbane/6/2012 are A/Victoria/361/2011-like viruses;
*** B/Hubei-Wujiagang/158/2009 and B/Texas/6/2011 are B/Wisconsin/1/2010-like viruses;
**** B/Brisbane/33/2008 is a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2012-13 Northern Hemisphere Influenza Season
23 February 2012
Recommended composition of influenza virus vaccines for use in the 2012-2013 Northern Hemisphere influenza season. It is recommended that vaccines for use in the 2012-2013 influenza season (Northern Hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus;
a B/Wisconsin/1/2010-like virus.
Source: World Health Organization
2012 Southern Hemisphere Influenza Season
Recommended composition of influenza virus vaccines for use in the 2012 Southern Hemisphere influenza season. It is recommended that vaccines for use in the 2012 influenza season (Southern Hemisphere) contain the following: an A/California/7/2009 (H1N1)pdm09-like virus; an A/Perth/16/2009 (H3N2)-like virus; a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2011-12 Northern Hemisphere Influenza Season
Recommended composition of influenza virus vaccines for use in the 2011-2012 Northern Hemisphere influenza season. It is recommended that vaccines for use in the 2011-2012 influenza season (Northern Hemisphere) contain the following:
an A/California/7/2009 (H1N1)-like virus;
an A/Perth/16/2009 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
Source: World Health Organization
2011 Southern Hemisphere Influenza Season
Recommended composition of influenza virus vaccines for use in the 2011 Southern Hemisphere influenza season. It is recommended that vaccines for use in the 2011 influenza season (Southern Hemisphere winter) contain the following:
— an A/California/7/2009 (H1N1)-like virus;
— an A/Perth/16/2009 (H3N2)-like virus;*
— a B/Brisbane/60/2008-like virus.
* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses.
Source: World Health Organization
2010-11 Northern Hemisphere Influenza Season
Recommended viruses for influenza vaccines for use in the 2010-2011 Northern Hemisphere influenza season. It is recommended that the following viruses be used for influenza vaccines in the 2010-2011 influenza season (Northern Hemisphere):
an A/California/7/2009 (H1N1)-like virus;
an A/Perth/16/2009 (H3N2)-like virus;*
a B/Brisbane/60/2008-like virus.
* A/Wisconsin/15/2009 is an A/Perth/16/2009 (H3N2)-like virus and is a 2010 southern hemisphere vaccine virus.
Source: World Health Organization
